FDA Requests Antidepressant Labeling Add Warning On Suicidality

The public health advisory and labeling change request follows an advisory committee recommendation for a stronger warning on the possible risks of the medications. The warning encourages health care providers to monitor patients closely for suicidal behavior although a link between the medications and suicide has not been established.